Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) announced on November 19, 2026 that its wholly owned subsidiary Filament Health Corp. has been issued a new United States patent titled "Psychoactive Alkaloid Extraction and Composition with Inhibited Dephosphorylation." The grant brings Filament's total to 79 issued patents across 13 patent families, strengthening what the company describes as the most extensive intellectual property estate in natural psilocybin. The new patent adds further protection around PEX010, Filament's standardised botanical psilocybin drug candidate currently supporting more than 80 studies worldwide.

Key Points

  • Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) made the announcement through subsidiary Filament Health Corp.
  • The United States Patent and Trademark Office issued a new patent covering psychoactive alkaloid extraction and composition with inhibited dephosphorylation.
  • Filament's patent estate now stands at 79 issued patents across 13 patent families, spanning the United States, Canada, Australia, Israel, Mexico, and Europe.
  • Investors may be watching how this expanded intellectual property position supports PEX010's role across more than 80 active research studies.

New Patent Covers Extraction and Dephosphorylation Inhibition for PEX010

The newly issued patent, titled "Psychoactive Alkaloid Extraction and Composition with Inhibited Dephosphorylation," was granted by the United States Patent and Trademark Office to Filament Health Corp. The release states that the patent extends protection over methods central to how PEX010 is manufactured, including extraction, purification, and stabilisation processes. The company asserts this grant adds to what it believes is the broadest natural psilocybin patent estate globally, covering a range of technical areas from extraction and purification through to standardised compositions and delivery mechanisms.

PEX010 Dosing Range and GMP Manufacturing Underpin Research Supply

PEX010 is described in the announcement as a standardised, GMP-manufactured botanical psilocybin drug candidate available in doses of 1, 5, and 25 mg from a single drug candidate, with a 0.5 mg dose stated to follow. The release emphasises that this standardised dosing range delivers consistent composition across every dose and research site, a characteristic the company positions as critical to its role supplying more than 80 academic and philanthropic studies worldwide. The immediate share price impact was not clear from available public information.

Filament Acquisition Completed April 30, 2026, Consolidating Patent Portfolio Under Rhelion

The release states that Rhelion completed its acquisition of Filament Health Corp. on April 30, 2026, bringing PEX010 and Filament's full patent portfolio under Rhelion's corporate structure. The combined patent estate now encompasses 79 issued patents across 13 patent families in jurisdictions including the United States, Canada, Australia, Israel, Mexico, and Europe. The disclosure suggests this consolidated intellectual property position is central to Rhelion's strategy of advancing naturally derived psychedelic drug candidates and supporting clinical research programs at leading institutions.